OSE Immunotherapeutics (OSE):企業の財務・戦略的SWOT分析

◆英語タイトル:OSE Immunotherapeutics (OSE) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH514015FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OSE Immunotherapeutics (OSE), formerly OSE Pharma SA, is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and breast cancer. It provides products such as tedopi and effi-7. OSE’s Effi-7 is in preclinical development and targets autoimmune diseases and transplantation. OSE’s tedopi stimulates cytotoxic killer T cells and relearns them to detect cancer cells to eliminate them. The company offers pipeline products such as OSE-172, OSE-703, FR104, 0SE-127. It markets its products through its distribution network. OSE is headquartered in Nantes, Pays-de-la-Loire, France.

OSE Immunotherapeutics Key Recent Developments

Mar 26,2021: OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update
Jan 28,2021: OSE Immunotherapeutics expands its collaboration with MAbSilico to use artificial intelligence to accelerate drug development of novel antibody therapeutics
Nov 09,2020: OSE Immunotherapeutics to present at SITC annual meeting and at additional international immuno-oncology summits
Sep 17,2020: OSE Immunotherapeutics reports first half 2020 results and corporate update
Jun 16,2020: OSE Immunotherapeutics announces results of 2020 virtual combined general meeting

This comprehensive SWOT profile of OSE Immunotherapeutics provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of OSE Immunotherapeutics including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

OSE Immunotherapeutics – Key Information
OSE Immunotherapeutics – Overview
OSE Immunotherapeutics – Key Employees
OSE Immunotherapeutics – Key Employee Biographies
OSE Immunotherapeutics – Key Operational Heads
OSE Immunotherapeutics – Major Products and Services
OSE Immunotherapeutics – History
OSE Immunotherapeutics – Company Statement
OSE Immunotherapeutics – Locations And Subsidiaries
OSE Immunotherapeutics
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

OSE Immunotherapeutics – Business Description
OSE Immunotherapeutics – Corporate Strategy
OSE Immunotherapeutics – SWOT Analysis
SWOT Analysis – Overview
OSE Immunotherapeutics – Strengths
OSE Immunotherapeutics – Weaknesses
OSE Immunotherapeutics – Opportunities
OSE Immunotherapeutics – Threats
OSE Immunotherapeutics – Key Competitors

Section 3 – Company Financial Performance Charts

OSE Immunotherapeutics – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

OSE Immunotherapeutics, Key Information
OSE Immunotherapeutics, Key Ratios
OSE Immunotherapeutics, Share Data
OSE Immunotherapeutics, Major Products and Services
OSE Immunotherapeutics, History
OSE Immunotherapeutics, Key Employees
OSE Immunotherapeutics, Key Employee Biographies
OSE Immunotherapeutics, Key Operational Heads
OSE Immunotherapeutics, Other Locations
OSE Immunotherapeutics, Subsidiaries
OSE Immunotherapeutics, Key Competitors
OSE Immunotherapeutics, SWOT Analysis
OSE Immunotherapeutics, Ratios based on current share price
OSE Immunotherapeutics, Annual Ratios
OSE Immunotherapeutics, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[OSE Immunotherapeutics (OSE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NFP Corp.:企業のM&A・事業提携・投資動向
    NFP Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NFP Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Adaptimmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics Plc is a clinical stage biotechnology company that develops T-cell therapy products for the treatment of cancer. The company’s pipeline peptides include NY-ESO TCR used to treat cancer cells, MAGE A-10 TCR used for the t …
  • Genentech, Inc.:企業の戦略・SWOT・財務分析
    Genentech, Inc. - Strategy, SWOT and Corporate Finance Report Summary Genentech, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sharps Compliance Corp (SMED):企業の財務・戦略的SWOT分析
    Summary Sharps Compliance Corp (Sharps) is a healthcare waste solution company that offers regulatory compliant services. The company offers products such as sharps disposal systems, public sharps safety, takeaway medication recovery system, collection and disposal system, complete needle collection …
  • Fresenius Kabi USA LLC:企業の戦略的SWOT分析
    Fresenius Kabi USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Episurf Medical AB (EPIS B):企業の製品パイプライン分析
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. It offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, Episealer …
  • Klox Technologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary Klox Technologies Inc (Klox Technologies) is a specialty pharmaceutical company, which focuses on the development and commercialization of a proprietary BioPhotonic technology platform. Its pipeline portfolio includes non-invasive wound care treatment solutions, dermatological treatment solu …
  • AusTex Oil Ltd:企業の戦略的SWOT分析
    AusTex Oil Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Johnson Electric Holdings Limited:企業の戦略・SWOT・財務情報
    Johnson Electric Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Johnson Electric Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Duke Energy Ohio Inc:企業の戦略的SWOT分析
    Duke Energy Ohio Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Pro-Dex Inc (PDEX):医療機器:M&Aディール及び事業提携情報
    Summary Pro-Dex Inc (Pro-Dex) is a medical device company that manufactures and markets surgical devices. The company’s products include motion control, finished medical devices, plastic injection molding, micro air-motors, dental products and torque wrenches. Its dental products comprise DLS handpi …
  • Ultra Petroleum Corp.:企業の戦略・SWOT・財務分析
    Ultra Petroleum Corp. - Strategy, SWOT and Corporate Finance Report Summary Ultra Petroleum Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mega Uranium Ltd (MGA):企業の財務・戦略的SWOT分析
    Mega Uranium Ltd (MGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AWE Ltd (AWE)-石油・ガス分野:企業M&A・提携分析
    Summary AWE Ltd (AWE) is an independent upstream oil and gas company. It focuses on the exploration, production and sale of oil, gas and condensate. The company has a diverse portfolio of upstream assets in Australia, New Zealand, and Indonesia. Its producing assets include BassGas project in Tasman …
  • Suzlon Energy Ltd (SUZLON):電力:M&Aディール及び事業提携情報
    Summary Suzlon Energy Ltd (Suzlon) is a provider of renewable energy solutions. It offers total solutions package that covers the entire wind energy projects scope. The company provides complete turnkey solutions from design to lifecycle asset management. Suzlon also generates electricity; and sells …
  • Lakewood-Amedex Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lakewood-Amedex Inc (Lakewood-Amedex) is a clinical-stage pharmaceutical company with focus on the development of antimicrobial and antifungal medicines to address unmet needs in the treatment of serious infectious diseases. The company develops anti-infective products such as anti-bacterial …
  • Sharjah Electricity & Water Authority:企業の戦略的SWOT分析
    Sharjah Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Medigen Biotechnology Corp (3176)-医療機器分野:企業M&A・提携分析
    Summary Medigen Biotechnology Corp (MBC) is a pharmaceutical company that carries out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. It focuses at developing new therapeutics, principally in the area of cancer and liver diseases. The company’s pro …
  • European Investment Bank:企業の戦略的SWOT分析
    European Investment Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Koninklijke Ten Cate NV:企業の戦略的SWOT分析
    Koninklijke Ten Cate NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆